MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1039/d6mh01360k

Медицинская библиотека · Materials horizons · 2026

A modified chitosan-based inflammation-regulating nanoplatform as a noninvasive carrier for macromolecular ophthalmic drug delivery toward synergistic AMD treatment.

Zhao Haibin, Zhang Qiang, Shen Jingjing, Fang Yuan, Lv Xinying, Miao Yu, Ma Baoye, Shuai Siyu, Hou Zhuyu, Chen Linfu, Yang Yang, Chen Qian

СтатьяПеревод пока не подготовлен

Аннотация

Age-related macular degeneration (AMD) is a prevalent cause of irreversible vision loss in the elderly worldwide. Current standard treatment relies on repeated intravitreal injection of anti-vascular endothelial growth factor A (anti-VEGFA), which is associated with invasiveness, poor patient compliance, and variable therapeutic responses. To address this, we developed an ocular-penetrating carrier for topical anti-VEGFA delivery by conjugating eicosapentaenoic acid (EPA) to chitosan (CS), yielding EPA-functionalized chitosan (CS-EPA). Interestingly, CS-EPA retains the antioxidant and anti-inflammatory activities of EPA while enhancing ocular penetration by promoting E-cad redistribution and transient tight-junction modulation. It self-assembles with therapeutic proteins through electrostatic interactions, forming stable nanocomplexes, which can efficiently reach the posterior segment of mice after non-invasive eye drop administration. More importantly, in a laser-induced choroidal neovascularization (CNV) mouse model, CS-EPA/anti-VEGFA eye drops inhibited neovascularization as effectively as intravitreal anti-VEGFA injection. Beyond VEGFA neutralization, CS-EPA directly suppressed the nuclear factor-κB (NF-κB) pathway, reduced pro-inflammatory cytokine production, and alleviated oxidative stress, thereby disrupting the inflammation-angiogenesis cycle driving AMD progression. Therefore, the dual-action CS-EPA, with enhanced ocular penetration and intrinsic anti-inflammatory activity, provides a noninvasive, patient-compliant alternative for AMD treatment and holds promise for treating other posterior segment diseases.

Для цитирования: Zhao Haibin, Zhang Qiang, Shen Jingjing, Fang Yuan, Lv Xinying, Miao Yu, Ma Baoye, Shuai Siyu, Hou Zhuyu, Chen Linfu, Yang Yang, Chen Qian. A modified chitosan-based inflammation-regulating nanoplatform as a noninvasive carrier for macromolecular ophthalmic drug delivery toward synergistic AMD treatment.. Materials horizons. 2026. DOI: 10.1039/d6mh01360k.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.